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Table 1: Types of vector and considerations in relation to placental directed gene therapy for FGR 
Vector DNA Efficiency Tropism Advantages Disadvantages Placental gene therapy 
considerations 
Non-viral DNA no limit + Limited Low toxicity  
Low immunogenicity 
Low transduction 
efficiency 
Expression may not last 
through gestation 
Adenovirus 
 
7.5kb +++  Depends on serotype Can grow to high titre 
Highly efficient gene transfer 
Clinical safety and efficacy data 
long term in adults 
Short term expression & 
immunogenic 
 
Helper-
dependent 
Adenovirus 
35kb +++ Broad Low immunogenicity, high 
capacity, long-term expression in 
quiescent  cells 
Inefficient production  
Adeno-
associated 
virus 
4.7 kb 
generally 
++ Depends on sub-type Long term expression 
Low immunogenicity 
Very high titre 
Clinical safety and efficacy data 
long term in adults 
Liver toxicity in adult 
trials due to anti-capsid 
T cells. 
Risk of hepatocellular 
cancer. 
Some subtypes associated 
with miscarriage 
Low level integration into 
active genes so theoretical 
mutagenesis risk. 
Retrovirus 10kb + Depends on 
pseudotyping 
Long term gene transfer 
Clinical safety and efficacy data 
long term in neonates 
Potential for insertional 
mutagenesis. 
Infect dividing cells only. 
Risk of germ-line 
transmission and insertional 
mutagenesis 
Lentivirus 10kb ++ Depends on 
pseudotyping 
Long term gene transfer 
Infects dividing and non-dividing 
cells 
Potential for insertional  
mutagenesis 
Risk of germ-line 
transmission and insertional 
mutagenesis  
Non-
integrating 
lentivirus 
10kb ++ Depends on 
pseudotyping 
Insertional mutagenesis unlikely 
 
Short term expression Rapidly dividing placental 
cells may result in long term 
low transgenic protein 
expression 
 
